Cost-Effectiveness Analysis of Umeclidinium Bromide/Vilanterol 62.5/25 MCG Versus Tiotropium/Olodaterol 5/5 MCG in Symptomatic Patients with Chronic Obstructive Pulmonary Disease in Spain
Matthew Taylor and Michelle Green provide a valuable insight into methods of vital cost-effectiveness analysis of combination inhalers for the management of chronic obstructive pulmonary disease.